

# Min Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5698536/publications.pdf>

Version: 2024-02-01

93  
papers

5,980  
citations

101543

36  
h-index

76900

74  
g-index

94  
all docs

94  
docs citations

94  
times ranked

7210  
citing authors

#	ARTICLE	IF	CITATIONS
1	DJ-1 and $\alpha$ -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726.	7.6	575
2	Plasma exosomal $\alpha$ -synuclein is likely CNS-derived and increased in Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 128, 639-650.	7.7	504
3	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580.	5.3	371
4	Phosphorylated $\alpha$ -Synuclein in Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 121ra20.	12.4	223
5	Salivary $\alpha$ -synuclein and DJ-1: potential biomarkers for Parkinson's disease. <i>Brain</i> , 2011, 134, e178-e178.	7.6	196
6	Transmission of $\alpha$ -synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?. <i>Acta Neuropathologica Communications</i> , 2017, 5, 71.	5.2	188
7	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 480, 78-82.	2.1	184
8	CSF $A\beta_{42}$ and tau in Parkinson's disease with cognitive impairment. <i>Movement Disorders</i> , 2010, 25, 2682-2685.	3.9	162
9	SNCA Variant Associated With Parkinson Disease and Plasma $\alpha$ -Synuclein Level. <i>Archives of Neurology</i> , 2010, 67, 1350-6.	4.5	157
10	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1125-1131.	0.8	154
11	Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 299-305.	2.6	153
12	Rab11a and HSP90 Regulate Recycling of Extracellular $\alpha$ -Synuclein. <i>Journal of Neuroscience</i> , 2009, 29, 1480-1485.	3.6	128
13	Cerebrospinal Fluid $\alpha$ -Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort. <i>American Journal of Pathology</i> , 2014, 184, 966-975.	3.8	126
14	New windows into the brain: Central nervous system-derived extracellular vesicles in blood. <i>Progress in Neurobiology</i> , 2019, 175, 96-106.	5.7	121
15	Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. <i>Acta Diabetologica</i> , 2019, 56, 581-592.	2.5	110
16	Biomarker discovery in neurodegenerative diseases: A proteomic approach. <i>Neurobiology of Disease</i> , 2009, 35, 157-164.	4.4	102
17	Glycoproteomics in neurodegenerative diseases. <i>Mass Spectrometry Reviews</i> , 2010, 29, 79-125.	5.4	99
18	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. <i>American Journal of Pathology</i> , 2011, 178, 1509-1516.	3.8	97

#	ARTICLE	IF	CITATIONS
19	DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. <i>Scientific Reports</i> , 2012, 2, 954.	3.3	90
20	ALYREF mainly binds to the 5' and the 3' regions of the mRNA in vivo. <i>Nucleic Acids Research</i> , 2017, 45, 9640-9653.	14.5	87
21	CSF tau and tau/A $\beta$ 242 predict cognitive decline in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 271-276.	2.2	81
22	Mortalin: A Protein Associated With Progression of Parkinson Disease?. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2008, 67, 117-124.	1.7	77
23	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. <i>Acta Neuropathologica</i> , 2013, 126, 671-682.	7.7	76
24	Identification of Glutathione S-Transferase Pi as a Protein Involved in Parkinson Disease Progression. <i>American Journal of Pathology</i> , 2009, 175, 54-65.	3.8	75
25	$\beta$ -Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 679-688.	2.6	74
26	Phosphorylated $\beta$ -synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 7.	5.2	74
27	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020, 143, 1780-1797.	7.6	66
28	Erythrocytic $\beta$ -Synuclein as a potential biomarker for Parkinson's disease. <i>Translational Neurodegeneration</i> , 2019, 8, 15.	8.0	65
29	Identification of Synaptosomal Proteins Binding to Monomeric and Oligomeric $\beta$ -Synuclein. <i>PLoS ONE</i> , 2015, 10, e0116473.	2.5	63
30	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 544-555.	3.8	51
31	Tau Proteins Cross the Blood-Brain Barrier. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 411-419.	2.6	50
32	Proteomics Identification of Proteins in Human Cortex Using Multidimensional Separations and MALDI Tandem Mass Spectrometer. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1818-1823.	3.8	44
33	Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. <i>Journal of Internal Medicine</i> , 2014, 276, 470-485.	6.0	42
34	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. <i>Scientific Reports</i> , 2018, 8, 2098.	3.3	42
35	Anti-Inflammatory Pyranochalcone Derivative Attenuates LPS-Induced Acute Kidney Injury via Inhibiting TLR4/NF- $\kappa$ B Pathway. <i>Molecules</i> , 2017, 22, 1683.	3.8	41
36	Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 109-117.	2.8	40

#	ARTICLE	IF	CITATIONS
37	Intronless mRNAs transit through nuclear speckles to gain export competence. <i>Journal of Cell Biology</i> , 2018, 217, 3912-3929.	5.2	40
38	Cerebrospinal fluid amyloid $\beta$ and tau in <i>LRRK2</i> mutation carriers. <i>Neurology</i> , 2012, 78, 55-61.	1.1	39
39	Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 1802-1808.	5.6	38
40	Coniferaldehyde attenuates Alzheimer's pathology <i>via</i> activation of Nrf2 and its targets. <i>Theranostics</i> , 2020, 10, 179-200.	10.0	37
41	Proteomic Analysis of Saliva from Patients with Oral Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1048-1055.	2.0	35
42	Pharmacological Inhibition of Fatty Acid-Binding Protein 4 (FABP4) Protects Against Rhabdomyolysis-Induced Acute Kidney Injury. <i>Frontiers in Pharmacology</i> , 2018, 9, 917.	3.5	35
43	DJ-1 and $\beta$ -SYN in <i>LRRK2</i> CSF do not correlate with striatal dopaminergic function. <i>Neurobiology of Aging</i> , 2012, 33, 836.e5-836.e7.	3.1	34
44	Premature termination codons are recognized in the nucleus in a reading-frame-dependent manner. <i>Cell Discovery</i> , 2015, 1, .	6.7	34
45	Cerebrospinal fluid $\beta$ -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.8	34
46	Anti-diabetic vanadyl complexes reduced Alzheimer's disease pathology independent of amyloid plaque deposition. <i>Science China Life Sciences</i> , 2019, 62, 126-139.	4.9	34
47	Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 397-416.	3.9	34
48	Identification of proteins in human substantia nigra. <i>Proteomics - Clinical Applications</i> , 2008, 2, 776-782.	1.6	33
49	Biomarkers for Cognitive Impairment in Parkinson Disease. <i>Brain Pathology</i> , 2010, 20, 660-671.	4.1	33
50	Four new monomeric insulins obtained by alanine scanning the dimer-forming surface of the insulin molecule. <i>Protein Engineering, Design and Selection</i> , 2000, 13, 779-782.	2.1	30
51	Targeted Discovery and Validation of Plasma Biomarkers of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2014, 13, 4535-4545.	3.7	30
52	Cheek cell-derived $\beta$ -synuclein and DJ-1 do not differentiate Parkinson's disease from control. <i>Neurobiology of Aging</i> , 2014, 35, 418-420.	3.1	30
53	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid $\beta$ 1-42 in CSF for the Diagnosis of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2017, 16, 1228-1238.	3.7	30
54	<i>ALYREF</i> links 5' end processing to nuclear export of non-polyadenylated mRNA s. <i>EMBO Journal</i> , 2019, 38, .	7.8	30

#	ARTICLE	IF	CITATIONS
55	A Longitudinal Study of Total and Phosphorylated $\alpha$ -Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1541-1553.	2.6	29
56	Plasma $\alpha$ -synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. <i>Neurobiology of Disease</i> , 2018, 116, 53-59.	4.4	29
57	Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 274.	3.5	29
58	Diagnostic Values of Cerebrospinal Fluid T-Tau and $A\beta^{242}$ using Meso Scale Discovery Assays for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 709-719.	2.6	28
59	Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. <i>European Journal of Pharmacology</i> , 2020, 887, 173570.	3.5	28
60	Erythrocytic $\alpha$ -synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 102.	5.2	26
61	Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 779-787.	2.3	25
62	Ethanol extract of <i>Liriodendron chinense</i> (Hemsl.) Sarg barks attenuates hyperuricemic nephropathy by inhibiting renal fibrosis and inflammation in mice. <i>Journal of Ethnopharmacology</i> , 2021, 264, 113278.	4.1	24
63	Pharmacological Inhibition of Macrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alleviates Rhabdomyolysis-induced Acute Kidney Injury. <i>Chinese Medical Journal</i> , 2017, 130, 2163-2169.	2.3	23
64	Renal Protective Effects of 17 $\beta$ -Estradiol on Mice with Acute Aristolochic Acid Nephropathy. <i>Molecules</i> , 2016, 21, 1391.	3.8	22
65	Inhibition of Fatty Acid-binding Protein 4 Attenuated Kidney Fibrosis by Mediating Macrophage-to-Myofibroblast Transition. <i>Frontiers in Immunology</i> , 2020, 11, 566535.	4.8	22
66	Immunoregulation of microglial polarization: an unrecognized physiological function of $\alpha$ -synuclein. <i>Journal of Neuroinflammation</i> , 2020, 17, 272.	7.2	22
67	Mechanistic Insights of Soluble Uric Acid-related Kidney Disease. <i>Current Medicinal Chemistry</i> , 2020, 27, 5056-5066.	2.4	22
68	Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 909-923.	0.8	21
69	Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1484-1497.	1.6	20
70	Role of Fatty Acid Binding Protein 4 (FABP4) in Kidney Disease. <i>Current Medicinal Chemistry</i> , 2020, 27, 3657-3664.	2.4	20
71	Microbial and metabolomic remodeling by a formula of Sichuan dark tea improves hyperlipidemia in apoE-deficient mice. <i>PLoS ONE</i> , 2019, 14, e0219010.	2.5	18
72	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying $\alpha$ -Synuclein-containing Extracellular Vesicles. <i>Neurology</i> , 2021, 96, e2332-e2345.	1.1	18

#	ARTICLE	IF	CITATIONS
73	CSF $\alpha$ -synuclein, tau, and amyloid $\beta$ in Parkinson's disease. <i>Lancet Neurology</i> , 2011, 10, 681.	10.2	15
74	Extracellular microvesicles-derived from microglia treated with unaggregated $\alpha$ -synuclein attenuate mitochondrial fission and toxicity-induced by Parkinsonian toxin MPP+. <i>Biochemical and Biophysical Research Communications</i> , 2019, 517, 642-647.	2.1	13
75	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 263-276.	2.6	13
76	A U2-snRNP-independent role of SF3b in promoting mRNA export. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7837-7846.	7.1	13
77	Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease. <i>Life Sciences</i> , 2021, 285, 119946.	4.3	13
78	Identification of ciliary neurotrophic factor receptor $\alpha$ as a mediator of neurotoxicity induced by $\alpha$ -synuclein. <i>Proteomics</i> , 2010, 10, 2138-2150.	2.2	12
79	Quantitative Proteomic Analysis of Oligodendrogliomas With and Without 1p/19q Deletion. <i>Journal of Proteome Research</i> , 2010, 9, 2610-2618.	3.7	12
80	Quantitative Characterization of Glycoproteins in Neurodegenerative Disorders Using iTRAQ. <i>Methods in Molecular Biology</i> , 2013, 951, 279-296.	0.9	11
81	Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 371-379.	0.8	10
82	Combining clinical and biofluid markers for early Parkinson's disease detection. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 109-114.	3.7	10
83	Catheter Failure and Mortality in Hemodialysis Patients with Tunneled Cuffed Venous Catheters in a Single Center. <i>Blood Purification</i> , 2017, 43, 321-326.	1.8	9
84	An $\alpha$ -synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700045.	1.6	9
85	Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 37.	5.2	8
86	Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker. <i>Clinical Cancer Research</i> , 2020, 26, 193-205.	7.0	6
87	Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogues in mouse mammary tumor cells. <i>IUBMB Life</i> , 1997, 43, 705-711.	3.4	1
88	Case Report: Efficiency of Embolization Microcoils for the Repair of Brachiocephalic Vein Perforation During Hemodialysis Catheter Placement. <i>Frontiers in Medicine</i> , 2021, 8, 726120.	2.6	1
89	Microinjection and Fluorescence In Situ Hybridization Assay for Studying mRNA Export in Mammalian Cells. <i>Methods in Molecular Biology</i> , 2017, 1648, 95-102.	0.9	0
90	FP420PHARMACOLOGICAL INHIBITION OF FATTY ACID BINDING PROTEIN-4 (FABP4) PROTECTS AGAINST DIABETIC NEPHROPATHY IN DB/DB MICE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i176-i177.	0.7	0

#	ARTICLE	IF	CITATIONS
91	FP041INHIBITION OF FATTY ACID BINDING PROTEIN-4 (FABP4) ALLEVIATES HYPERURICEMIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i61-i61.	0.7	0
92	Comparison of the Growth Promoting Effects of Serum Transferrins from Different Animals on Mouse Mammary Tumor Cell Line GR2H6. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica Et Biophysica Sinica, 1998, 30, 101-103.	0.1	0
93	An Assay System for the Growth Promoting Activity of Insulin by (3)H-thymidine Incorporation. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica Et Biophysica Sinica, 1997, 29, 88-91.	0.1	0